The value of real-world evidence in supporting targeted therapies for patients with rare oncogenic drivers in mNSCLC.

Abstract excerpt

With the ongoing discovery of various oncogenic driver mutations in metastatic non-small cell lung cancer (mNSCLC), a precision medicine approach has emerged, characterized by targeted therapies for select patient populations. Randomized controlled trials (RCT) remain the gold standard for evaluating efficacy and safety of such therapies; however, RCTs evaluating treatments for rare oncogenic drivers still face...

Topics

Join the communities discussing this publication.

• Biomarkers, Tumor
• Carcinoma, Non-Small-Cell Lung
• Clinical Decision-Making
• Lung Neoplasms
• Molecular Targeted Therapy